Pazopanib shortage status
2 active shortage notices across 2 countries.
Last updated 2 Aug 2026 · sourced from official medicines regulators
- Generic name (INN)
- Pazopanib
- Brand names
- Teva
- Class
- Auto-created by Pharmac — New Zealand Medicine Supply Disruptions scraper
Where Pazopanib is in shortage
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| Italy | critical | 1 | 31 Aug 2026 | — | AIFA |
| New Zealand | high | 1 | 1 Apr 2026 | — | Pharmac |
Why Pazopanib is in shortage
- manufacturing problems — e.g. “Problemi produttivi” (Italy)
- supply-chain disruption — e.g. “Due to manufacturing changes, there is limited stock of the 200 mg strength of pazopanib tablets (Pharmacode: 2695332).” (New Zealand)
Frequently asked questions
Is Pazopanib currently in shortage?
Yes. As of the latest regulator updates, Pazopanib has 2 active shortage notices across 2 countries (Italy, New Zealand). Status is refreshed daily from official regulatory sources.
Why is Pazopanib in shortage?
Regulators attribute the current Pazopanib shortages to manufacturing problems, supply-chain disruption. The exact cause varies by country and product — each notice on this page links to the official source.
Where does this Pazopanib shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Get alerted when Pazopanib status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.